Estrogen-independent effects of ER-α36 in ER-negative breast cancer

被引：46

作者：

Zhang, Jing ^{[2
,3
]}

Li, Guangliang ^{[2
]}

Li, Zhongqi ^{[2
]}

Yu, Xiongfei ^{[2
]}

Zheng, Yi ^{[4
]}

Jin, Ketao ^{[2
]}

Wang, Haohao ^{[2
]}

Gong, Yun ^{[3
]}

Sun, Xiaoping ^{[5
]}

Teng, Xiaodong ^{[6
]}

Cao, Jiang ^{[1
]}

Teng, Lisong ^{[2
]}

机构：

[1] Zhejiang Univ, Clin Res Ctr, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China

[2] Zhejiang Univ, Dept Surg Oncol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China

[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[4] Zhejiang Univ, Dept Med Oncol, Affiliated Hosp 1, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China

[5] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77030 USA

[6] Zhejiang Univ, Dept Pathol, Affiliated Hosp 1, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China

来源：

STEROIDS | 2012年 / 77卷 / 06期

基金：

中国国家自然科学基金;

关键词：

Estrogen receptor-alpha 36; Breast cancer; Paclitaxel; Metastasis; RECEPTOR-ALPHA; ADJUVANT CHEMOTHERAPY; VARIANT; EXPRESSION; PACLITAXEL; INHIBITION; RESISTANCE; APOPTOSIS; PROTEIN; KINASE;

D O I：

10.1016/j.steroids.2012.02.013

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Estrogen receptor-alpha 36 (ER-alpha 36) is a variant of ER-alpha that has been found to be expressed in conventional ER (ER-alpha 66)-negative breast cancer cell lines and human breast cancer samples. In this study, we found that, using immunohistochemical study. ER-alpha 36 expression was significantly higher in ER-negative tumors than in ER-positive tumors although the expression was not associated with other clinicopathological characteristics. We then constructed an ER-alpha 36-specific microRNA hairpin vector and established stable ER-alpha 36 knockdown cells, and found that the knockdown cells were more sensitive to paclitaxel; the c-Jun N-terminal kinase pathway appeared to be involved in the mechanism. Downregulation of ER-alpha 36 also resulted in decreased migration and invasion. These changes were estrogen independent. Our findings indicated that target ER-alpha 36 may be a strategy for treating ER-negative breast cancers. (c) 2012 Elsevier Inc. All rights reserved.

引用

页码：666 / 673

页数：8

共 50 条

[1] Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells
Zhang, Xin-Tian
Ding, Ling
Kang, Lian-Guo
Wang, Zhao-Yi
ONCOLOGY REPORTS, 2012, 27 (06) : 2057 - 2065
[2] ER-α36, a novel variant of estrogen receptor-α, mediates membrane-initiated mitogenic estrogen signaling in ER-negative breast cancer cells
Shen, P
Zhang, XT
Loggie, BW
Wang, ZY
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S246 - S246
[3] A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells
Zhang, X. T.
Kang, L. G.
Ding, L.
Vranic, S.
Gatalica, Z.
Wang, Z-Y
ONCOGENE, 2011, 30 (07) : 770 - 780
[4] A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells
X T Zhang
L G Kang
L Ding
S Vranic
Z Gatalica
Z-Y Wang
Oncogene, 2011, 30 : 770 - 780
[5] ER-α36, a novel variant of estrogen receptor-alpha, mediates membrane-initiated mitogenic estrogen signaling in ER-negative breast cancer cells
Wang, Zhaoyi
Zhang, Xintian
Shen, Peng
CANCER RESEARCH, 2006, 66 (08)
[6] ER-α36, a variant of ER-α, is the estrogen receptor that mediates mitogenic estrogen signaling in breast cancer cells
Ding, L.
Zhang, X. T.
Wang, Z. Y.
CANCER RESEARCH, 2009, 69 (02) : 68S - 68S
[7] A new estrogen receptor on ER-negative breast cancer?
Peralta, E.
Paris, B. D.
Kamel, O. W.
Louis, S.
Dunnington, G. L.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[8] Targeting estrogen to kill ER-positive and ER-negative breast cancer
Jordan, VC
BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S4 - S4
[9] Targeting estrogen to kill ER-positive and ER-negative breast cancer
VC Jordan
Breast Cancer Research, 7
[10] Sex Hormones and Risk of Estrogen Receptor (ER)-Positive and ER-Negative Breast Cancer
Farhat, G. N.
Cummings, S. R.
Parimi, N.
Huang, A.
Cauley, J. A.
Rohan, T. E.
Hubbell, F. A.
Vitolins, M.
Manson, J. E.
Chlebowski, R. T.
Lee, J.
CANCER RESEARCH, 2009, 69 (24) : 533S - 533S

← 1 2 3 4 5 →